Galmed PharmaceuticalsEOCN
13F holders, Q3 2025 (September 30)14holders −1
3new positions
4sold out
1famous investor
$1.40avg. 13F price*
At the end of Q3 2025, 14 institutions reported holding Galmed Pharmaceuticals Ltd. (EOCN) in their 13F filings, down 1 from Q2 2025. 3 opened new positions and 4 sold out. The largest holders were Citadel Advisors ($71K), Two Sigma Investments, LP ($29K) and UBS Group AG ($1K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Galmed Pharmaceuticals Ltd.
- CUSIP
- M47238148
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $100K |
| Exits | 4 | $62K |
All 13F filers, Q2 2025 → Q3 2025: 71,713 shares bought and 74,876 shares sold, net −3,163 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Citadel Advisors | 0.00% | New | 50,492 | $71K |
| Two Sigma Investments, LP | 0.00% | New | 21,200 | $29K |
| UBS Group AG | 0.00% | Reduce -86.0% | 963 | $1K |
| Morgan Stanley | 0.00% | Reduce -99.7% | 98 | $135 |
| Wealthspire Advisors, LLC | 0.00% | New | 21 | $29 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -99.2% | 16 | $22 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 14 | $19 |
| Wells Fargo & Company | 0.00% | No change | 9 | $12 |
| Osaic Holdings, Inc. | 0.00% | No change | 5 | $6 |
| Allworth Financial LP | 0.00% | No change | 2 | $3 |
| TD Waterhouse Canada Inc. | 0.00% | No change | 2 | $3 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 1 | $2 |
| Dogwood Wealth Management LLC | 0.00% | No change | 1 | $1 |
| Tsfg, LLC | 0.00% | No change | 17 | $0 |
"% of holder's portfolio" is EOCN's weight in each manager's 13F, not the share of Galmed Pharmaceuticals Ltd. the manager owns.